Genetik Lifesciences To Produce Affordable Aphotericin B Injection To Treat Black Fungus Infection In COVID Patients

·1-min read

The Wardha-based Genetik Lifesciences has received the approval from the Food and Drug Administration (FDA) to produce the Amphotericin B injection for the black fungus infection during the Covid-19 period.

This initiative was led by the Union Minister of Road Transport and Highways Nitin Gadkari, who is also the MP of Nagpur that is located nearby to Wardha.

The production of Amphotericin B will commence at the Wardha plant of the company in the coming fortnight.

This content is not available due to your privacy preferences.
Update your settings here to see it.

“On the initiative of Union Minister @nitin_gadkari, Wardha's Genetic Life Sciences has received FDA approval to manufacture Amphotericin B injection for black fungus infection (Mucormycosis) occurring during the corona period. Its production will start in Wardha in 15 days,” the senior minister’s office confirmed in its official Twitter handle.

The injection is currently priced at around Rs 7,000, something that has blocked its access to the masses. However, Genetik Lifesciences will make the same available at a cost of only Rs 1,200 as it is set to produce 20,000 injections on a daily basis in its plant.

In fact, the company on Wednesday (12 May) already kicked off the manufacturing of the vital Remdesivir injection that is widely used to treat patients infected with Covid-19, The Economic Times reports.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting